{
  "ticker": "BMRN",
  "company_name": "BioMarin Pharmaceutical Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT05368038",
      "title": "ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program",
      "status": "ENROLLING_BY_INVITATION",
      "phase": "",
      "condition": "Acid Sphingomyelinase Deficiency, Ceroid Lipofuscinosis, Neuronal, 2, Cerebrotendinous Xanthomatosis, Fabry Disease, GM1 Gangliosidosis, Gaucher Disease, Lysosomal Acid Lipase Deficiency, Metachromatic Leukodystrophy, Mucopolysaccharidosis II, Mucopolysaccharidosis III-B, Mucopolysaccharidosis IV A, Mucopolysaccharidosis VI, Mucopolysaccharidosis VII, Niemann-Pick Disease, Type C",
      "start_date": "2021-05-10",
      "completion_date": "2029-08-31",
      "enrollment": 0,
      "sponsor": "Albert Einstein College of Medicine"
    },
    {
      "nct_id": "NCT03864029",
      "title": "Retrospective Observational Safety Effectiveness With Kuvan in hpA",
      "status": "COMPLETED",
      "phase": "",
      "condition": "Tetrahydrobiopterin Deficiency",
      "start_date": "2017-10-10",
      "completion_date": "2018-07-25",
      "enrollment": 0,
      "sponsor": "BioMarin Pharmaceutical"
    },
    {
      "nct_id": "NCT02049593",
      "title": "PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Metastatic Cancer, Unspecified Adult Solid Tumor",
      "start_date": "2014-06-12",
      "completion_date": "2019-10-07",
      "enrollment": 0,
      "sponsor": "Jonsson Comprehensive Cancer Center"
    }
  ],
  "summary": {
    "total_trials": 3,
    "by_phase": {
      "": 2,
      "PHASE1": 1
    },
    "by_status": {
      "ENROLLING_BY_INVITATION": 1,
      "COMPLETED": 2
    },
    "active_trials": 1,
    "completed_trials": 2,
    "conditions": [
      "Acid Sphingomyelinase Deficiency, Ceroid Lipofuscinosis, Neuronal, 2, Cerebrotendinous Xanthomatosis, Fabry Disease, GM1 Gangliosidosis, Gaucher Disease, Lysosomal Acid Lipase Deficiency, Metachromatic Leukodystrophy, Mucopolysaccharidosis II, Mucopolysaccharidosis III-B, Mucopolysaccharidosis IV A, Mucopolysaccharidosis VI, Mucopolysaccharidosis VII, Niemann-Pick Disease, Type C",
      "Metastatic Cancer, Unspecified Adult Solid Tumor",
      "Tetrahydrobiopterin Deficiency"
    ],
    "lead_stage": "phase_1"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-12T09:33:25.153933",
    "search_query": "BioMarin Pharmaceutical Inc.",
    "url": "https://clinicaltrials.gov/search?term=BioMarin+Pharmaceutical+Inc."
  }
}